))
3: Disappointing Data. Cosentyx Doesn’t Deliver in Giant Cell Arteritis
Manage episode 493054964 series 3675738
Content provided by The HEII. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The HEII or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Novartis’ blockbuster Cosentyx has hit a wall. In this episode of The Biotech Brief, we unpack the Phase 3 GCAptAIN trial results, where Cosentyx failed to show benefit for patients with giant cell arteritis. We explore what GCA is, why this label expansion mattered, and how the drug—once seen as a contender in this space—fell short. Plus, we look at the commercial implications, the competitive IL-6 landscape, and what this means for the future of Cosentyx and Novartis’ inflammatory disease pipeline.
6 episodes
Share
